Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions characterized by excess neural excitability, such as rare neurological disorders, epilepsies, and seizure-related issues. The company advances a pipeline targeting neuronal hyperexcitability to restore excitatory-inhibitory balance in the brain. Key programs include OV329, a next-generation GABA-aminotransferase inhibitor designed to increase GABA levels for treatment-resistant seizures with potentially improved safety over prior drugs, currently in Phase 1 clinical trials. Ovid Therapeutics also develops a portfolio of KCC2 direct activators, including OV350 as an intravenous tool compound evaluated in Phase 1 for foundational safety data, and OV4071, an oral candidate prioritized for neuropsychiatric conditions like psychosis in Parkinson's disease and Lewy body dementia. Additional compounds from its proprietary KCC2 library support oral and injectable formulations for neurological, neurodevelopmental, and neurodegenerative applications. Founded in 2014 and headquartered in New York, Ovid Therapeutics concentrates on biomarker-driven development for central nervous system disorders with significant unmet needs.